Clinical Trial Results:
An Eight-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Dose Ranging Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of Oral Solabegron (GW427353) 250mg, 125mg, and 50mg administered Twice Daily vs Placebo, in Women with Overactive Bladder
Summary
|
|
EudraCT number |
2005-005431-97 |
Trial protocol |
FI DE SI LV ES |
Global completion date |
15 Feb 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Nov 2016
|
First version publication date |
24 Nov 2016
|
Other versions |
|
Summary report(s) |
gsk-104833-synopsis-redact |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.